Close Menu

Biomarker Discovery & Validation

News on biomarker discovery and validation for research and diagnostic use in genetics, genomics, and molecular diagnostics.

Researchers will use the grant to develop a drug testing platform using patient-derived tumor organoids to predict treatment outcomes for patients.

The partners will use Akoya's multiplex immunofluorescence platform for spatial phenotyping and JHU's AstroPath platform to identify predictive signatures.

The partners will use mass spec to look at markers in Barrett's patients who either progressed to more severe disease states or remained stable over a 10-year period.

Tempus has been providing Bristol Myers Squibb with de-identified transcriptomic datasets to help in the identification of new cancer biomarkers.

The startup biotech has spent four years researching PRDM genes in various cancers and is coming out of stealth mode with a lead candidate in lung cancer.

Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

May
26
Sponsored by
Lexogen

The emergence of cell clones that are resistant to targeted therapies poses a significant issue in the treatment of metastatic melanoma.

Jun
16
Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.